uPA Inhibitor II, UK122 (CAS 1186653-73-5)
See product citations (5)
QUICK LINKS
uPA Inhibitor II, UK122 is a compound that functions as an inhibitor of urokinase-type plasminogen activator (uPA). It exerts its mechanism of action by targeting and binding to the active site of uPA, thereby preventing the conversion of plasminogen to plasmin. This inhibition ultimately leads to the suppression of proteolytic activity, which is for the degradation of extracellular matrix components. By interfering with the proteolytic function of uPA, uPA Inhibitor II, UK122 plays a role in regulating processes such as cell migration, invasion, and tissue remodeling. Upa Inhibitor Ii, Uk122′s mechanism of action involves disrupting the enzymatic activity of uPA, thereby influencing the proteolytic cascade and associated cellular behaviors. UPA Inhibitor II, UK122 functions as a specific inhibitor of uPA, modulating its proteolytic activity and impacting cellular processes involved in tissue homeostasis and remodeling.
uPA Inhibitor II, UK122 (CAS 1186653-73-5) References
- Identification of a novel inhibitor of urokinase-type plasminogen activator. | Zhu, M., et al. 2007. Mol Cancer Ther. 6: 1348-56. PMID: 17431113
- Regulation of cell migration and invasion by specific modules of uPA: mechanistic insights and specific inhibitors. | Carriero, MV., et al. 2011. Curr Drug Targets. 12: 1761-71. PMID: 21707476
- Neuroprotection by urokinase plasminogen activator in the hippocampus. | Cho, E., et al. 2012. Neurobiol Dis. 46: 215-24. PMID: 22293605
- Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling. | Stewart, AG., et al. 2013. Br J Pharmacol. 170: 1421-35. PMID: 24111848
- Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer. | Banyard, J., et al. 2014. BMC Cancer. 14: 387. PMID: 24885350
- The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF. | Schuliga, M., et al. 2017. Sci Rep. 7: 41770. PMID: 28139758
- Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors. | Stepanova, V., et al. 2017. J Biol Chem. 292: 20528-20543. PMID: 28972182
- Tetrahydroindolocarbazoles (THICZs) as new class of urokinase (uPA) inhibitors: Synthesis, anticancer evaluation, DNA-damage determination, and molecular modelling study. | El-Sharief, MAMS., et al. 2018. Bioorg Chem. 80: 545-554. PMID: 30014922
- Excess hepsin proteolytic activity limits oncogenic signaling and induces ER stress and autophagy in prostate cancer cells. | Willbold, R., et al. 2019. Cell Death Dis. 10: 601. PMID: 31399560
- Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells. | Osawa, M., et al. 2021. Anticancer Res. 41: 645-660. PMID: 33517269
- Discovery of a novel inhibitor against urokinase-type plasminogen activator, a potential enzyme with a role in atherosclerotic plaque instability. | Ganguly, R., et al. 2023. J Biomol Struct Dyn. 41: 3485-3495. PMID: 35362361
- Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice. | Kida, Y., et al. 2023. Sci Rep. 13: 2899. PMID: 36806262
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
uPA Inhibitor II, UK122, 5 mg | sc-356185 | 5 mg | $588.00 |